Individualized Tamoxifen Dose Escalation-Response
Clin Cancer Res
.
2016 Dec 15;22(24):6301.
doi: 10.1158/1078-0432.CCR-16-2351.
Authors
Daniel L Hertz
1
,
James M Rae
2
Affiliations
1
Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan. DLHertz@med.umich.edu.
2
Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan Medical School, Ann Arbor, Michigan.
PMID:
27980025
PMCID:
PMC8330639
DOI:
10.1158/1078-0432.CCR-16-2351
No abstract available
Publication types
Letter
Comment
MeSH terms
Antineoplastic Agents, Hormonal*
Dose-Response Relationship, Drug
Humans
Tamoxifen*
Substances
Antineoplastic Agents, Hormonal
Tamoxifen
Grants and funding
R01 GM099143/GM/NIGMS NIH HHS/United States